Screener
Rein Therapeutics Inc. RNTX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Rein Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Rein Therapeutics Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 7:56 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225352
| Revenue | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Total operating expenses | 5,230 | 5,609 |
| Loss from operations | (5,230) | (5,609) |
| Other (expense) income, net | (608) | 108 |
| Net loss | $(5,838) | $(5,501) |
| Net loss per share—basic and diluted | $(0.19) | $(0.25) |
| Weighted average common shares outstanding—basic and diluted | 30,354,647 | 21,915,891 |
| Comprehensive loss: | ||
| Net loss | $(5,838) | $(5,501) |
Item 1. Financial Statements.
FAQ
- What is Rein Therapeutics Inc.'s net income?
- Rein Therapeutics Inc. (RNTX) reported net income of -$5.84M in Q1 2026.
- How has Rein Therapeutics Inc.'s net income changed year-over-year?
- Rein Therapeutics Inc.'s net income decreased by 6.1% year-over-year, from -$5.5M to -$5.84M.
- What is the long-term trend for Rein Therapeutics Inc.'s net income?
- Over 4 years (2021 to 2025), Rein Therapeutics Inc.'s net income has grown at a 17.5% compound annual growth rate (CAGR), from -$26.16M to -$49.87M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Rein Therapeutics Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude